283 results about "Chimera Protein" patented technology

The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.

The invention discloses a method for improving the inductivity and genetic transformation efficiency of hairy roots of toona ciliata. According to the method, agrobacterium rhizogenes carrying RUBY-TcGRF8-GIF2 chimeric protein are injected into stems and petioles of aseptic seedlings of the toona ciliata, and the TcGRF8-GIF2 chimeric gene is over-expressed, so that the induction efficiency and the genetic transformation efficiency of the toona ciliata hairy roots are remarkably improved, and the transformation period of the toona ciliata hairy roots is remarkably shortened. Specifically, after overexpression of the TcGRF8-GIF2 gene, the induction time of the hairy roots is shortened from 70 days of a RUBY-XbaI no-load plasmid control group to 25 days, the induction rate and conversion rate of the hairy roots mediated by agrobacterium tumefaciens are improved, the operation efficiency of genetic transformation of the toona ciliata is effectively improved, and the method has important significance for promoting genetic improvement of the toona ciliata.

The invention discloses a rice large-scale metabolism regulator DGP1 and crop metabolism quality design. The invention finds that the structural domain of the rice DGP1 family protein TIGR01589 targets a plurality of metabolic enzymes and promotes the metabolic enzymes to be transferred to a cell nucleus; the structural domain also has an intervention effect on a light breathing pathway by changing the composition of a glycine decarboxylase compound in mitochondria. Based on a molecular mechanism of DGP1, a chimeric protein ST containing a conservative structural domain and coupled with a chloroplast positioning signal is designed, and genetic engineering modification of pakchoi is realized. The modification strategy not only can guide substrate flow of a central glycolysis pathway to flavonoid biosynthesis, but also can promote accumulation of saccharides derived from photosynthetic products in leaves.

The present invention provides a nucleic acid molecule encoding a chimeric protein useful for efficient production of phycocyanobilin, a genetic vector and a host cell comprising a nucleotide sequence encoding the chimeric protein, a modified cell capable of expressing the chimeric protein, the chimeric protein, and a method for producing phycocyanobilin using the chimeric protein.

The present application provides chimeric proteins comprising an antibody moiety that specifically binds to a component of an influenza virus or a variant thereof, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating an infection caused by an influenza virus or a variant thereof in an individual.

Provided herein are combinations for inhibiting tyrosine kinase activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and / or symptomology of the disease.

The invention belongs to the technical field of bioengineering, and particularly relates to an IL-12-CD137 chimeric protein, a function-enhanced engineered NK cell, and preparation and application thereof. The IL-12-CD137 chimeric protein comprises a signal peptide, an IL-12a protein molecule, a CD137 transmembrane structural domain and a CD137 intracellular structural domain, and has an amino acid sequence as shown in SEQ ID NO: 1. According to the function-enhanced engineered NK cell, the IL-12-CD137 chimeric protein sequence is introduced into an original NK cell, the function-enhanced engineered NK cell expressing Chime-IL12-CD137 is obtained, the amplification capacity and killing capacity of the NK cell can be enhanced, and the function-enhanced engineered NK cell is applied to treatment of tumor and virus-infected diseases of companion animals for the first time.

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

The invention relates to a purification and renaturation method of a recombinant chimeric protein inclusion body, which comprises the following steps: adding arginine into an inclusion body renaturation solution to improve the stability of renatured protein, adding reduced glutathione and oxidized glutathione at the same time, and adjusting the concentration, proportion and other process parameters of the reduced glutathione, the oxidized glutathione and the reduced glutathione to obtain the recombinant chimeric protein inclusion body. The renaturation effect and the yield of the denatured inclusion body protein are further improved.

The invention relates to an endoplasmic reticulum-based chimeric protein construct for targeting protein degradation and application thereof, for example, the chimeric protein construct is used for treating cancers, virus infectious diseases, autoimmune diseases, neurodegenerative diseases and the like. The chimeric protein constructs comprise an endoplasmic reticulum-related degradation mechanism protein binding domain and a targeting domain. The ERAD mechanism protein binding domain of the chimeric protein construct may be a transmembrane domain of a viral endoplasmic reticulum resident protein or a functional variant thereof and an endoplasmic reticulum resident domain or a functional variant thereof. The targeting domain of the chimeric protein construct can target any target protein of interest, which can be a natural ligand of the target protein, an antibody that specifically recognizes the target protein, or an antigen-binding fragment thereof. The targeting domain of the chimeric protein construct may also be an antigen that can be specifically recognized by an antibody.

Provided herein are IL-2 prodrugs, as well as methods of using the same to modulate the immune system in a subject.

The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and / or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.

The present invention belongs to the field of immunology and relates to proteins and polypeptides comprising an immunoglobulin single variable domain (ISVD) fused with a cytokine. In particular, the present invention provides a chimeric protein which comprises an immunoglobulin single variable domain (ISVD) fused with a cytokine, wherein an internal fusion site of the ISVD is linked to the cytokine, wherein the internal fusion site is located in a loop or turn between two secondary structure elements. The fusion of the cytokine to the ISVD upon binding to the cytokine receptor or receptor subunit(s) allows for the modulation of the cytokine receptor activity and / or downstream signaling.

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen, which comprises the following antigen components: at least one fusion protein or chimeric protein formed by mycobacterium tuberculosis early secretion antigens Ag85A and Ag85B and / or immunocompetence fragments thereof, at least one mycobacterium tuberculosis PE / PPE family antigen Rv1759c (PE-PGRS family protein WAG22) or immunocompetence fragments thereof, and at least one immunocompetence fragment thereof, and at least one mycobacterium tuberculosis latent associated antigen Rv1813c or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

The present invention provides a non-human animal expressing human or chimeric LPA and / or human or chimeric APOB proteins and methods of use thereof.

The present disclosure relates to compositions and methods for modifying target nucleic acids, and methods for detecting nucleic acids. Various compositions are described herein, including compositions comprising an endonuclease, an endonuclease system, and a chimeric protein having the endonuclease and a nucleic acid modulating domain or a nucleic acid modifying domain.

Some aspects of the disclosure relate to mRNA vaccines encoding chimeric proteins and variants thereof, including portions of coronavirus nucleocapsid (N), matrix (M), non- structural protein 3 (Nsp3), and / or Spike (S). Also provided are methods of using the vaccines.

The disclosure relates to compositions and methods to trans-splice RNA, as well as methods to treat, ameliorate, or a prevent a disease or disorder using the trans-splicing system described herein. Various compositions are described herein, including compositions comprising endonucleases, endonuclease systems, and chimeric proteins having the endonuclease and a nucleic-acid modulating domain or a nucleic acid modifying domain.

The disclosure relates to compositions and methods that modify target nucleic acids, as well as methods of detecting nucleic acids. Various compositions are described herein, including compositions comprising endonucleases, endonuclease systems, and chimeric proteins having the endonuclease and a nucleic-acid modulating domain or a nucleic acid modifying domain.

To provide a method for propagating a recombinant influenza B virus, and a host cell.SOLUTION: A method for propagating a recombinant influenza B virus comprising a mutant BM2 gene having a specific sequence comprises: contacting a host cell with the recombinant influenza B virus; and incubating the host cell for a sufficient time and under conditions suitable for viral replication; where the host cell is an MDCK cell or a Vero cell expressing functional BM2 or chimeric M2-BM2 proteins.SELECTED DRAWING: None

The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotting factor and an Fc region.

The present application provides, in part, pharmaceutical formulations of Clec9A-based chimeric protein complexes and uses thereof.

Provided herein are compounds, preferably (R)-N-(4-(chlorodifluoromethoxy) phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide having the Formula Ior a pharmaceutically acceptable salt or tautomer thereof, that inhibits tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and / or symptomology of the disease.

Aspects of the present disclosure include chimeric proteins and engineered host cells that comprise the chimeric proteins. Another aspect of the present disclosure include methods of reducing porphyrins or derivatives thereof from recombinant proteins expressed or secreted from the engineered host cell. Another aspect of the present disclosure includes methods of making recombinant proteins from the engineered host cells.

To provide a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker.SOLUTION: The present invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, and a chain comprising a VWF protein and a chain comprising a FVIII protein are associated with each other. The method also comprises a method for using a nucleotide, a vector, a host cell, and a chimeric protein.SELECTED DRAWING: None

The present invention discloses an aromatic amine compound and its application. The aromatic amine compound can effectively inhibit the tyrosine kinase activity of Abelson protein (ABL1), Abelson-associated protein (ABL2) and related chimeric proteins, especially BCR-ABL1. The aromatic amine compound can be used to prepare inhibitors of Abelson protein (ABL1), Abelson-associated protein (ABL2) and related chimeric proteins, and can be used as a drug for treating diseases related to abnormal activity of BCR-ABL1 fusion protein.

The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D′ domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.

The present application provides, in part, pharmaceutical formulations of Clec9A-based chimeric protein complexes, and uses thereof.

Provided herein are cells expressing a first and a second chimeric protein in the cell membrane. Such cells can solve expression problems of CAR constructs caused by these CAR construct's ability to recognize unwanted internal epitopes or exhibiting unwanted signalling due to misfolding / scFv aggregation. The first chimeric protein comprises an extracellular antigen binding unit and an intracellular dimerization domain. The second chimeric protein comprises a lipid anchoring domain, an intracellular dimerization domain and a signaling domain. Accordingly, the expression of the two proteins allows them to translocate to the cell membrane without much interference and subsequently gain signaling capacity when colocalized at the cell membrane.